Skip to main content
MorphoSys AG logo

MorphoSys AG — Investor Relations & Filings

Ticker · MOR ISIN · DE000A3H2XW6 LEI · 529900493806K77LRE72 F Manufacturing
Open in API
Filings indexed 1,418 across all filing types
Latest filing 2002-01-22 Board/Management Inform…
Country DE Germany
Listing F MOR

About MorphoSys AG

https://www.morphosys.com/

MorphoSys AG is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines, primarily for cancer patients. The company specializes in creating therapeutic monoclonal antibodies, utilizing its long-standing expertise and proprietary technology platforms to generate fully human antibodies. Its research and development efforts are concentrated on building a pipeline of novel treatments to address significant unmet medical needs in oncology. In February 2024, Novartis entered into an agreement to acquire MorphoSys, aiming to integrate its antibody technologies and oncology pipeline.

Recent filings

Filing Released Lang Actions
MorphoSys AG english
Board/Management Information Classification · 99% confidence The document is a corporate news announcement dated January 22, 2002, detailing the hiring of key personnel for the clinical development team, specifically naming the new Medical Director and Head of Clinical Research and Development, Dr. Axel Mescheder, and describing his background and reporting structure. This content directly relates to changes in senior management and key personnel within the company's operational structure. This aligns perfectly with the definition for Board/Management Information (MANG). It is not an earnings release, a full annual report, or a proxy statement.
2002-01-22 English
MorphoSys AG english
Regulatory Filings Classification · 100% confidence The document is a short corporate news announcement dated January 8, 2002, detailing an expansion of a collaboration agreement between MorphoSys AG and Biogen, Inc. It discusses research, licensing payments, and drug target identification. This content does not fit the specific definitions for financial reports (10-K, IR, ER), shareholder actions (AGM-R, DVA), management changes (MANG), or specific financial events (CAP, DIV, POS). It is a general corporate update regarding business operations and partnerships. Since it is a specific business announcement that doesn't fit the highly specialized categories, the most appropriate fallback category is 'Regulatory Filings' (RNS), which serves as a general category for miscellaneous corporate announcements not covered elsewhere.
2002-01-08 English
MorphoSys AG english
M&A Activity Classification · 99% confidence The document is an 'Ad-hoc' announcement dated December 20, 2001, detailing a strategic collaboration and equity purchase between MorphoSys AG and Schering AG. This type of announcement, which details a significant corporate event like a major partnership, financing component (equity purchase), and future collaboration terms, does not fit neatly into the specific categories like 10-K, ER, or IR. It is a general regulatory announcement concerning corporate activity. Since it is not a report itself, nor a specific notice like a dividend or director dealing, the most appropriate fallback category is 'Regulatory Filings' (RNS), as it is a general, time-sensitive regulatory disclosure.
2001-12-20 English
MorphoSys AG english
Regulatory Filings Classification · 100% confidence The document is an 'Ad-hoc' announcement dated November 28, 2001, detailing the development and release of a new proprietary antibody library (HuCAL GOLD). This is a specific operational/technology update, not a standard financial report (like 10-K, IR, ER) or a standard corporate governance filing (like DEF 14A, DVA). It announces a significant development intended to be a 'cornerstone of a future Company product development program.' Since it is a specific, non-standard announcement that doesn't fit the primary financial or governance categories, and it is not a general report publication announcement (RPA), the most appropriate classification is the general 'Regulatory Filings' fallback category (RNS), as it is an ad-hoc disclosure.
2001-11-28 English
MorphoSys AG english
Earnings Release Classification · 100% confidence The document is explicitly titled "MorphoSys Announces Third Quarter Results" and provides key financial figures (revenues, operating expenses, net loss) for the third quarter and nine months ended September 30, 2001. This content structure—reporting period results and key operational highlights—is characteristic of an Earnings Release (ER). Although it contains some AGM information (shareholder assembly), the primary focus and structure are financial results reporting, making ER the most appropriate classification over AGM-R or IR (Interim Report), as ER is typically the initial, brief announcement of these figures. 9M 2001
2001-11-13 English
MorphoSys AG english
Regulatory Filings Classification · 100% confidence The document is an 'Ad-hoc' announcement dated October 17, 2001, detailing the issuance of a US Patent for MorphoSys AG's HuCAL Antibody Library. This type of announcement, which reports on specific, material, non-scheduled corporate events (like patent grants or legal updates) that are not standard periodic reports (10-K, IR, ER), typically falls under general regulatory announcements or specific legal/IP categories. Since there is no specific category for 'Patent Grant Announcement,' and it is a formal, material announcement transmitted via DGAP (a regulatory news service), it best fits the 'Regulatory Filings' (RNS) category, which serves as a general category for miscellaneous regulatory announcements not covered elsewhere. It is too specific for 'LTR' (Legal Proceedings Report) as it concerns IP protection, not litigation. It is not a standard financial report, presentation, or management change.
2001-10-17 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.